fishing meme

What is it? From hand-wired vintage-style showpieces to modern high-gain amp juggernauts, Blackstar is the kind of company that can do it all and do it well. But perhaps the one thing it should be applauded for more than anything else is bringing boutique tube amp sounds to just about any kind of guitar player out there – marrying tone, durability and affordability better than arguably any other guitar amp brand to emerge over the last two decades. Specs Launch price: $649 / £599 / €719 Type: Tube combo Origin: China Output: 10 Watts RMS Speaker: 1x 12" Celestion Seventy 80 Channels: One Controls: Gain, Tone, Reverb, Master, Boost Connectivity: Emulated/headphone out, series effects loop with level switch, three speaker outs Footswitch: Included (boost) Weight: 32.4lbs / 14.7kg Dimensions (WxHxD): 473 x 421 x 251 mm Contact: Blackstar Amplification Build quality Build quality rating: ★★★★☆ This latest combo amp is the British-voiced sibling of the TV-10 A, and naturally uses an EL34 power tube in place of the 6L6 found on the other model, though beyond that, the specs are pretty much the same. As for first impressions, it definitely seems like Blackstar has been upping its game – not that there was anything particularly wrong with the look of its earlier small combo amps – but there’s definitely more of a classy aesthetic to its latest innovations. This combo comes in an olive finish with gold piping, plus a salt and pepper grill cloth, which means it’s incredibly inviting to play. Usability Usability rating: ★★★★★ Right off the bat, that sense of sophistication spills over into how it sounds, with our Custom Shop Masterbuilt Stratocaster going straight in and all controls set to noon. With only four dials, it’s very user-friendly, covering almost everything you could possibly want for practising, rehearsing and smaller gigs. In fact, it’s deceptively full and loud for a 10-watt combo, thanks to the combination of the clever circuitry and the Celestion Seventy 80 1x12 speaker . It comes as little surprise that the digital reverb emulates a classic spring tank very nicely indeed, and at the back you’ll also find a series effects loop if you want to use your own ambiance. There’s a foot-switchable boost to give you that all-important lift for solos to cut through, though players who depend on a fully customizable second channel will need something more feature-rich. Sounds Sounds rating: ★★★★☆ With the gain set low, you’re in vintage JTM45 territory, and what you hear is very musical and warm – ideal for a woody blues that allows the instrument in your hands to shine. It’s a sound that will inspire almost every kind of player, with a perfect balance of dynamic range and natural compression to help the notes ring. Turn it up a bit more and you’ll recognize a familiar Plexi crunch that will suit all your favourite Cream and Led Zeppelin classics with no need for extra pedals, especially if you’re using a humbucker -equipped guitar like my own 1969 Gibson Les Paul Custom. Beyond that, the TV-10 B can deliver a harder rock sound that goes a little further than the early Marshalls that inspired it, though still avoids anything too modern-leaning. There is only one Tone dial, and of course in an ideal world you’d have a three-band EQ, but it’s worth remembering this is an amp with old-school roots – that very notion of simplicity is quite possibly the key selling point. The TV-10 B also functions well as a pedal platform amp. We stacked an Ibanez TS808HW Tube Screamer with a Boss Blues Driver and a Ceriatone Centura with minimal noise or fuzz. Higher gain players will be the ones most affected by the lack of three-band EQ, meaning they’ll probably need a bass control on their pedal of choice in order to tighten things up, and modulations like the MXR Phase 90 , Pedal Pawn Gypsy Vibe and Dawner Prince Starla Tremolo can really intensify the sparkle and shimmer when engaged, tapping into more esoteric and ethereal musical realms. Verdict Clearly there’s a lot to like here, though the emulated/headphone output for recording or running direct through a PA is a bit hit-and-miss – it may come in handy for some users but doesn’t seem to carry the same kind of sonic weight as hearing the amp traditionally. It feels like more of an afterthought than an integral feature. Perhaps that’s because this nostalgic combo isn’t necessarily trying to be cutting edge, it’s more of a plug-in-and-play kind of design that specializes in vintage romance, which it brings in abundance. Guitar World verdict: The TV-10 B is both loud and proud while also being compact and classy. The direct out could be better, but what it truly excels at is simplicity – breathtaking sounds with just four knobs. For many of us, that’s all you can ask for. Also try Hands-on videos Blackstar Sweetwater AndertonsGisèle Benoit still gets goosebumps when she remembers the first time she saw a family of eastern wolves emerge from the forests of the Mauricie National Park, under the backdrop of a rising moon. It was 1984 and Benoit, then in her early 20s, had been using a horn to try to call a bull moose when she instead heard a long howl, followed by an adult wolf stepping out to a rocky shore accompanied by a half-grown youth and four pups. “I will never forget that,” she said of the magical moment. “It’s anchored in my heart forever.” It was only later that Benoit, an artist and documentary filmmaker, learned that the wolves she saw weren’t grey wolves but rather rare eastern wolves. The species, whose population is estimated at fewer than 1,000 mature adults, could soon be further protected by new measures that are raising hopes among conservationists that attitudes toward a once-feared and maligned animal are shifting. In July, the federal government upgraded the eastern wolf’s threat level from “status of special concern” to “threatened,” based on a 2015 report by the Committee on the Status of Endangered Wildlife in Canada. That report found the population count may be as low as 236 mature individuals in its central Ontario and southern Quebec habitat. The eastern wolf is described as medium-sized canid with reddish-tawny fur that lives in family groups of a breeding pair and their offspring. Also known as the Algonquin wolf, it is largely restricted to existing protected areas, including Algonquin Park in Ontario. The federal Environment Department said in an email that development of a recovery strategy is underway, adding it would be “written in collaboration with provincial governments, federal departments responsible for the federal lands where the eastern wolf is found as well as First Nations groups and Indigenous organizations.” The order triggers protection for the species on federal lands and forces Ottawa to prepare a recovery plan. However, the fight for protection could be an uphill battle in Quebec, which does not even recognize the eastern wolf as a distinct species. A spokesperson for Quebec’s Environment Department said Quebec considers the eastern wolf a “genetic group” rather than its own species. “Recent study shows that the eastern wolf is a distinct entity, even if it comes from several crosses between the grey wolf and the coyote,” Daniel Labonté wrote in an email. “However, scientific knowledge does not demonstrate that this genetic grouping constitutes a species in its own right.” Labonté added that this lack of recognition was not a barrier to protecting the animal, since the law also allows for protection of subspecies or wildlife populations. In October, Quebec launched a program to collect samples to improve knowledge on the distribution of large canines, including the eastern wolf. The government said it is currently “impossible to assert that there is an established population” in Quebec due to low numbers — amounting to three per cent of analyzed samples — and the “strong hybridization that exists among large canids.” Véronique Armstrong, co-founder of a Quebec wildlife protection association, says she’s feeling positive about both the Canadian and Quebec governments’ attitudes. While wolves were once “stigmatized, even persecuted,” she said, “we seem to be heading in the direction of more protection.” Her group, the Association québécoise pour la protection et l’observation de la faune, has submitted a proposal for a conservation area to protect southern Quebec wolves that has already received signs of support from three of the regional municipalities that would be covered, she said. While it’s far from settled, she’s hopeful that the battle to protect wolves might be easier than for some other species, such as caribou, because the wolves are adaptable and can tolerate some human activity, including forestry. John Theberge, a retired professor of ecology and conservation biology from the University of Waterloo and a wolf researcher, spent several years along with his wife studying and radio-collaring eastern wolves around Algonquin Park. Back in the 1990s and 2000s, they faced a “huge political battle” to try to expand wolf protection outside park boundaries after realizing that the far-ranging animals were being hunted and trapped in large numbers once they left the protected lands. Conservationists, he said, faced resistance from powerful hunter and trapper lobbies opposed to protecting the animals but in the end succeeded in permanently closing the zones outside the park to hunting and trapping in 2004. Theberge says people who want to save wolves today still face some of that same opposition — especially when governments including Quebec, Alberta and British Columbia kill wolves to protect endangered caribou. But he believes the public support for protecting wolves has increased from when his career began in the 1960s, when they were treated with fear and suspicion. “Nobody wore T-shirts with wolves on them back then,” he said. Over the years, there have been questions about whether the eastern wolf may be a grey wolf subspecies or a coyote-wolf hybrid. But in the order protecting the wolves, the federal government says genetic analyses have resolved that debate, showing that it is a “distinct species.” Benoit, Theberge and Armstrong all believe that while it’s important to protect the eastern wolf from a genetic diversity perspective, there is value in protecting all wolves, regardless of their DNA. Wolves, they say, are an umbrella species, meaning that protecting them helps protect a variety of other species. They kill off weak and sick animals, ensuring strong populations. They’re also “highly developed, sentient social species, with a division of labour, and strong family alliances,” Theberge said. Benoit agrees. After years spent watching wolves, she has developed great respect for how they live in close-knit families, with older offspring helping raise new pups. “It’s extraordinary to see how their way of life is a little like humans’,” she said.fishing meme 。

PM Modi asks states to provide environment for start-ups to flourishLG Electronics India is preparing for a Rs 15,000 crore IPO. LG's IPO is likely to be India's fifth-largest IPO after Life Insurance Corporation, Hyundai Motor, Paytm and Coal India. And among the concerns that LG has listed in its draft prospectus reportedly includes the company's South Korean parent company LG. According to a report in Economic Times, LG Electronics India has expressed concerns about potential future competition from its South Korean parent company. In its draft prospectus, the Indian subsidiary highlighted the lack of an exclusivity agreement, stating that while the parent currently doesn't compete in India, it reserves the right to do so, which could create conflicts of interest and negatively impact LG India 's business. LG India’s ‘big competition concern’ This concern extends to Hi-M Solutek India, an indirect, wholly-owned subsidiary specializing in LG commercial air conditioner service and maintenance. Although currently focused on LG products, there's no guarantee it won't expand to serve competitors or directly compete with LG India in the future. "While our promoter is currently not engaged in businesses that compete with ours in India, the promoter may in the future engage in businesses that compete with ours because we do not have any exclusivity arrangement with them," the company said in the draft prospectus. "This may give rise to conflicts of interest, which may adversely affect our business, financial condition and results of operations." "Currently, Hi-M Solutek India only provides services for our products. However, we do not have an exclusive contractual arrangement with them and there is no assurance that Hi-M Solutek India will not expand their business in the future to compete with ours or to provide services for our competitors," LG India said. "We plan to roll this out across our distribution network, which we believe will enable us to offer differentiated services, enhance consumer satisfaction and drive sales to consumers," the company said. The draft prospectus also says that LG India plans to build a new factory in Andhra Pradesh -- its third in the country. LG India is also scaling up component sourcing from its 280 local suppliers with the figure rising from 45% in 2022 to 58.3% in June this year.Assad’s fall: The end of Syria’s brutal ruling dynasty

NEW YORK (AP) — A slide for market superstar Nvidia on Monday knocked Wall Street off its big rally and helped drag U.S. stock indexes down from their records. The S&P 500 fell 0.6%, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average dipped 240 points, or 0.5%, and the Nasdaq composite pulled back 0.6% from its own record. Nvidia’s fall of 2.5% was by far the heaviest weight on the S&P 500 after China said it’s investigating the company over suspected violations of Chinese anti-monopoly laws. Nvidia has skyrocketed to become one of Wall Street’s most valuable companies because its chips are driving much of the world’s move into artificial-intelligence technology. That gives its stock’s movements more sway on the S&P 500 than nearly every other. Nvidia’s drop overshadowed gains in Hong Kong and for Chinese stocks trading in the United States on hopes that China will deliver more stimulus for the world’s second-largest economy. Roughly three in seven of the stocks in the S&P 500 also rose. The week’s highlight for Wall Street will arrive midweek when the latest updates on inflation arrive. Economists expect Wednesday’s report to show the inflation that U.S. consumers are feeling remained stuck at close to the same level last month. A separate report on Thursday, meanwhile, could show an acceleration in inflation at the wholesale level. They’re the last big pieces of data the Federal Reserve will get before its meeting next week on interest rates. The widespread expectation is still that the central bank will cut its main interest rate for the third time this year. The Fed has been easing its main interest rate from a two-decade high since September to offer more help for the slowing job market, after bringing inflation nearly all the way down to its 2% target. Lower interest rates can ease the brakes off the economy, but they can also offer more fuel for inflation. Expectations for a series of cuts from the Fed have been a major reason the S&P 500 has set so many all-time highs this year. “Investors should enjoy this rally while it lasts—there’s little on the horizon to disrupt the momentum through year-end,” according to Mark Hackett, chief of investment research at Nationwide, though he warns stocks could stumble soon because of how overheated they’ve gotten. On Wall Street, Interpublic Group rose 3.6% after rival Omnicom said it would buy the marketing and communications firm in an all-stock deal. The pair had a combined revenue of $25.6 billion last year. Omnicom, meanwhile, sank 10.2%. Macy’s climbed 1.8% after an activist investor, Barington Capital Group, called on the retailer to buy back at least $2 billion of its own stock over the next three years and make other moves to help boost its stock price. Super Micro Computer rose 0.5% after saying it got an extension that will keep its stock listed on the Nasdaq through Feb. 25, as it works to file its delayed annual report and other required financial statements. Earlier this month, the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board following the resignation of its public auditor . All told, the S&P 500 fell 37.42 points to 6,052.85. The Dow dipped 240.59 to 4,401.93, and the Nasdaq composite lost 123.08 to 19,736.69. In the oil market, a barrel of benchmark U.S. crude rallied 1.7% to settle at $68.37 following the overthrow of Syrian leader Bashar Assad, who sought asylum in Moscow after rebels. Brent crude, the international standard, added 1.4% to $72.14 per barrel. The price of gold also rose 1% to $2,685.80 per ounce amid the uncertainty created by the end of the Assad family’s 50 years of iron rule. In stock markets abroad, the Hang Seng jumped 2.8% in Hong Kong after top Chinese leaders agreed on a “moderately loose” monetary policy for the world’s second-largest economy. That’s a shift away from a more cautious, “prudent” stance for the first time in 10 years. A major planning meeting later this week could also bring more stimulus for the Chinese economy. U.S.-listed stocks of several Chinese companies climbed, including a 12.4% jump for electric-vehicle company Nio and a 7.4% rise for Alibaba Group. Stocks in Shanghai, though, were roughly flat. In Seoul, South Korea’s Kospi slumped 2.8% as the fallout continues from President Yoon Suk Yeol ’s brief declaration of martial law last week in the midst of a budget dispute. In the bond market, the yield on the 10-year Treasury rose to 4.19% from 4.15% late Friday. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.

Romania far-right candidate urges voters to turn up for scrapped electionProposed acquisition strengthens Pharming's late-stage pipeline with a potential first-in-disease asset Abliva's lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases Total transaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) Leiden, the Netherlands, December 15, 2024: Pharming Group N.V. ("Pharming" or "the Company") PHAR today announced a recommended public cash offer to the shareholders of Abliva AB ("Abliva") to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately US$66.1 million. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing medicines for the treatment of mitochondrial disease. Abliva's lead product, KL1333, a regulator of the essential co-enzymes NAD+ and NADH, is in a pivotal clinical study (FALCON) in adult patients with genetically confirmed primary mitochondrial disease (PMD) with mitochondrial DNA (mtDNA) mutations who experience consistent, debilitating fatigue and muscle weakness (myopathy), and reduced life expectancy. Over 30,000 patients diagnosed with mtDNA mitochondrial disease would be potentially addressable by KL1333 in the U.S., EU4 (France, Germany, Italy, Spain) and the UK. KL1333 has shown positive clinical effects in a proof-of-concept Phase 1b study, and a pre-planned interim analysis of the ongoing pivotal FALCON trial demonstrated promising differences over placebo in both alternate primary efficacy endpoints. KL1333 has received Fast Track designation in the U.S. and Orphan Drug Designation for the treatment of PMD in the U.S. and EU. Sijmen de Vries, Chief Executive Officer of Pharming, said: "Abliva has made exciting progress developing KL1333, a potential first-in-disease treatment undergoing a pivotal clinical trial that offers new hope to patients with rare mtDNA mitochondrial disease who experience debilitating fatigue and muscle weakness. With over 30,000 addressable patients in the U.S., EU4 and UK, we are excited about the potential of this asset, which achieved a positive interim analysis in the registration trial in July 2024. We believe KL1333 has blockbuster potential in the U.S. alone and can significantly change Pharming's future growth trajectory. We will fund this acquisition using existing cash, and anticipate covering costs to complete the pivotal trial with positive cash flows from our existing business. The acquisition of Abliva would further strengthen our clinical pipeline with the addition of a therapy, with U.S. launch expected in 2028, aligning with our vision to become a leading global rare disease company. We are pleased that Abliva's independent Board of Directors and major shareholders recognize the expertise and value Pharming brings to the development and eventual commercialization of KL1333, and unanimously support this transaction. We look forward to welcoming the Abliva team with their strong expertise in mitochondrial research and drug development and to combining with our resources, capabilities and commercial infrastructure to bring this groundbreaking and important medicine to patients and their healthcare providers." Transaction highlights Today at 19:45 CET, Pharming announced a recommended cash offer to the shareholders of Abliva AB. Hereby Pharming, through a wholly owned subsidiary, has offered SEK 0.45 in cash for each outstanding share of Abliva (the ''Offer''). The total value of the Offer based on all outstanding 1,611,884,536 shares in Abliva amounts to approximately SEK 725,348,041, or approximately US$66.1 million. The Board of Directors of Abliva unanimously recommends the shareholders of Abliva to accept the Offer. The Board of Directors of Abliva has obtained a fairness opinion from PwC, according to which, based on the assumptions and reservations stated in the opinion, the Offer is fair to Abliva's shareholders from a financial perspective. Pharming has obtained acceptance undertakings from the three largest shareholders, accounting for 49.82% of Abliva's outstanding shares. The Offer is subject to customary regulatory approvals, and Pharming expects to obtain such approvals prior to the end of the acceptance period. Pharming Group N.V. has cash on hand to finance the Offer in full. The acceptance period in the offer is expected to commence on or around January 16, 2025 and to expire on or around February 7, 2025. For information in relation to the Offer, please refer to www.raredisease-offer.com . An offer document will be made public by Pharming shortly before the commencement of the acceptance period. Van Lanschot Kempen N.V. is sole financial advisor and NautaDutilh N.V. and Mannheimer Swartling Advokatbyrå are legal advisors to Pharming in connection with the Offer. Invitation to conference call Pharming to host a conference call on Monday, December 16, 2024, at 14:00 CET (8:00 am EST). The conference call presentation is available on the pharming.com website from 14:00 CET on December 16, 2024 A transcript will be made available on the pharming.com website in the days following the call. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Conference call dial-in details: Please note, the Company will only take questions from dial-in attendees. https://register.vevent.com/register/BIfcd1fd2bdf0e443cbf6192dc063763ad Webcast Link: https://edge.media-server.com/mmc/p/2hfpccyi For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: investor@pharming.com FTI Consulting, London, UK Victoria Foster Mitchell/Alex Shaw/Amy Byrne T: +44 203 727 1000 LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: pharming@lifespring.nl Abliva investors Leo Wei T: +46 (0)709 910 081 E: pharming@fogelpartners.se About KL1333 KL1333 has been designed to treat chronic fatigue and myopathy (muscle weakness) in genetically confirmed adult patients with primary mitochondrial disease. Diagnoses can include MELAS-MIDD and KSS-CPEO spectrum disorders as well as MERRF syndrome. The drug candidate is intended for long-term oral treatment. KL1333 has the ability to restore the ratio of NAD+ and NADH, and thus leads to the formation of new mitochondria and improved energy levels. In a cohort of mitochondrial disease patients in a Phase 1a/b study, the patients who received KL1333 showed both improvements in symptoms of fatigue as well as functional improvements. KL1333 is currently being evaluated in a global, potentially registrational, Phase 2 study (the FALCON study) and has received orphan drug designation in both the USA and Europe as well as Fast Track designation in the USA. About the FALCON Study FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study evaluating the safety and efficacy of KL1333 in adult patients with primary mitochondrial disease who experience consistent, debilitating fatigue and myopathy (muscle weakness), the most common and impairing symptoms. A total of 180 patients with mitochondrial DNA mutations who meet the eligibility criteria are randomized 3:2 to receive KL1333 (50mg-100mg) or placebo twice daily for 48 weeks. The two alternative primary endpoints assess consistent fatigue (using the PROMIS® Fatigue Mitochondrial Disease Short Form) and myopathy (using the 30 second Sit-to-Stand test), only one of which must be positive to file for marketing approval. An interim analysis evaluating 24-week data from the first wave of patients confirmed the strong safety profile of KL1333, and both primary endpoints passed futility, meaning that both have the potential to demonstrate benefit in the final analysis of the study. About Abliva AB Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell's energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD+ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden ABLI . For more information, please visit www.abliva.com. About Pharming Group N.V. Pharming Group N.V. PHAR is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, and has employees around the globe who serve patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia-Pacific. For more information, visit www.pharming.com and find us on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as "aim", "ambition", ‘‘anticipate'', ‘‘believe'', ‘‘could'', ‘‘estimate'', ‘‘expect'', ‘‘goals'', ‘‘intend'', ‘‘may'', "milestones", ‘‘objectives'', ‘‘outlook'', ‘‘plan'', ‘‘probably'', ‘‘project'', ‘‘risks'', "schedule", ‘‘seek'', ‘‘should'', ‘‘target'', ‘‘will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates, Pharming's clinical and commercial prospects, and Pharming's expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory, commercial, competitive and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming's 2023 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information, future events or other information. Inside Information This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Attachment Pharming announces public cash offer to the shareholders of Abliva AB_EN_15DEC24 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Conservationists eager for plan to save rare eastern wolf in Quebec, Ontario

Biden calls for Assad to be 'held accountable'NEW YORK (AP) — A slide for market superstar Nvidia on Monday knocked Wall Street off its big rally and helped drag U.S. stock indexes down from their records. The S&P 500 fell 0.6%, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average dipped 240 points, or 0.5%, and the Nasdaq composite pulled back 0.6% from its own record. Nvidia’s fall of 2.5% was by far the heaviest weight on the S&P 500 after China said it’s investigating the company over suspected violations of Chinese anti-monopoly laws. Nvidia has skyrocketed to become one of Wall Street’s most valuable companies because its chips are driving much of the world’s move into artificial-intelligence technology. That gives its stock’s movements more sway on the S&P 500 than nearly every other. Nvidia’s drop overshadowed gains in Hong Kong and for Chinese stocks trading in the United States on hopes that China will deliver more stimulus for the world’s second-largest economy. Roughly three in seven of the stocks in the S&P 500 also rose. The week’s highlight for Wall Street will arrive midweek when the latest updates on inflation arrive. Economists expect Wednesday’s report to show the inflation that U.S. consumers are feeling remained stuck at close to the same level last month. A separate report on Thursday, meanwhile, could show an acceleration in inflation at the wholesale level. They’re the last big pieces of data the Federal Reserve will get before its meeting next week on interest rates. The widespread expectation is still that the central bank will cut its main interest rate for the third time this year. The Fed has been easing its main interest rate from a two-decade high since September to offer more help for the slowing job market, after bringing inflation nearly all the way down to its 2% target. Lower interest rates can ease the brakes off the economy, but they can also offer more fuel for inflation. Expectations for a series of cuts from the Fed have been a major reason the S&P 500 has set so many all-time highs this year. “Investors should enjoy this rally while it lasts—there’s little on the horizon to disrupt the momentum through year-end,” according to Mark Hackett, chief of investment research at Nationwide, though he warns stocks could stumble soon because of how overheated they’ve gotten. On Wall Street, Interpublic Group rose 3.6% after rival Omnicom said it would buy the marketing and communications firm in an all-stock deal. The pair had a combined revenue of $25.6 billion last year. Omnicom, meanwhile, sank 10.2%. Macy’s climbed 1.8% after an activist investor, Barington Capital Group, called on the retailer to buy back at least $2 billion of its own stock over the next three years and make other moves to help boost its stock price. Super Micro Computer rose 0.5% after saying it got an extension that will keep its stock listed on the Nasdaq through Feb. 25, as it works to file its delayed annual report and other required financial statements. Earlier this month, the maker of servers used in artificial-intelligence technology said an investigation found no evidence of misconduct by its management or by the company’s board following the resignation of its public auditor . All told, the S&P 500 fell 37.42 points to 6,052.85. The Dow dipped 240.59 to 4,401.93, and the Nasdaq composite lost 123.08 to 19,736.69. In the oil market, a barrel of benchmark U.S. crude rallied 1.7% to settle at $68.37 following the overthrow of Syrian leader Bashar Assad, who sought asylum in Moscow after rebels. Brent crude, the international standard, added 1.4% to $72.14 per barrel. The price of gold also rose 1% to $2,685.80 per ounce amid the uncertainty created by the end of the Assad family’s 50 years of iron rule. In stock markets abroad, the Hang Seng jumped 2.8% in Hong Kong after top Chinese leaders agreed on a “moderately loose” monetary policy for the world’s second-largest economy. That’s a shift away from a more cautious, “prudent” stance for the first time in 10 years. A major planning meeting later this week could also bring more stimulus for the Chinese economy. U.S.-listed stocks of several Chinese companies climbed, including a 12.4% jump for electric-vehicle company Nio and a 7.4% rise for Alibaba Group. Stocks in Shanghai, though, were roughly flat. In Seoul, South Korea’s Kospi slumped 2.8% as the fallout continues from President Yoon Suk Yeol ’s brief declaration of martial law last week in the midst of a budget dispute. In the bond market, the yield on the 10-year Treasury rose to 4.19% from 4.15% late Friday. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.Syrian insurgents reach the capital's suburbs. Worried residents flee and stock up on supplies BEIRUT (AP) — Insurgents’ stunning march across Syria is gaining speed with news that they have reached the suburbs of the capital of Damascus. The government on Saturday was forced to deny rumors that President Bashar Assad had fled the country. The rebels’ moves around Damascus were reported by an opposition war monitor and a rebel commander. They came after the Syrian army withdrew from much of southern part of the country, leaving more areas, including two provincial capitals, under the control of opposition fighters. The advances in the past week were among the largest in recent years by opposition factions. The factions are by a group that has its origins in al-Qaida and is considered a terrorist organization by the U.S. and the United Nations. An archbishop's knock formally restores Notre Dame to life as winds howl and heads of state look on PARIS (AP) — France’s iconic Notre Dame Cathedral has formally reopened its doors for the first time since a devastating fire nearly destroyed the 861-year-old landmark in 2019. The five-year restoration is widely seen as a boost for French President Emmanuel Macron, who championed the ambitious timeline, and brings a welcome respite from his domestic political woes. World leaders, dignitaries, and worshippers gathered on Saturday evening for the celebrations under the cathedral's soaring arches. The celebration was attended by 1,500 dignitaries, including President-elect Donald Trump, Britain’s Prince William, and Ukrainian President Volodymyr Zelenskyy. For Catholics, Notre Dame’s rector said the cathedral “carries the enveloping presence of the Virgin Mary, a maternal and embracing presence.′′ Trump is welcomed by Macron to Paris with presidential pomp and joined by Zelenskyy for their talks PARIS (AP) — French President Emmanuel Macron has welcomed Donald Trump to Paris with a full dose of presidential pomp. And they held a hastically-arranged meeting with Ukraine’s Volodymyr Zelenskyy on a day that's mixing pageantry with attention to pressing global problems. The president-elect's visit to France is part of a global a celebration of the reopening of Notre Dame Cathedral five years after a devastating fire. Macron and other European leaders are trying to win Trump’s favor and persuade him to maintain support for Ukraine in its defense against Russia’s invasion. Trump isn't back in office but he's already pushing his agenda and negotiating with world leaders NEW YORK (AP) — Donald Trump is making threats, traveling abroad, and negotiating with world leaders. He has more than a month-and-a-half to go before he’s sworn in for a second term. But the president-elect is already moving aggressively to not only fill his Cabinet and outline policy goals, but also to try to achieve his priorities. In recent days, Trump has threatened to impose a 25% tariff on goods from Canada and Mexico, two of the country’s largest trading partners. That led to emergency calls and a visit. And he's warned of “ALL HELL TO PAY” if Hamas doesn't release the hostages still being held captive in Gaza. South Korea's president avoids an impeachment attempt over short-lived martial law SEOUL, South Korea (AP) — South Korea’s embattled President Yoon Suk Yeol has avoided an opposition-led attempt to impeach him over his short-lived imposition of martial law. Most of Yoon's ruling party lawmakers boycotted a parliamentary vote Saturday to deny a two-thirds majority needed to suspend his presidential powers. The scrapping of the motion is expected to intensify protests calling for Yoon’s ouster and deepen political chaos in South Korea. A survey suggests a majority of South Koreans support the president’s impeachment. Yoon’s martial law declaration drew criticism from his own ruling conservative People Power Party. But the party also apparently fears losing the presidency to liberals. Days after gunman killed UnitedHealthcare's CEO, police push to ID him and FBI offers reward NEW YORK (AP) — Nearly four days after the shooting of UnitedHealthcare CEO Brian Thompson, police still do not know the gunman’s name or whereabouts or have a motive for the killing. But they have made some progress in their investigation into Wednesday's killing of the leader of the largest U.S. health insurer, including that the gunman likely left New York City on a bus soon after fleeing the scene. The also found that the gunman left something behind: a backpack that was discovered in Central Park. Police are working with the FBI, which on Friday night announced a $50,000 reward for information leading to an arrest and conviction. UnitedHealthcare CEO's shooting opens a door for many to vent frustrations over insurance The fatal shooting of UnitedHealthcare's CEO has opened the door for many people to vent their frustrations and anger over the insurance industry. The feelings of exasperation, anger, resentment, and helplessness toward insurers aren’t new. But the shooting and the headlines around it have unleashed a new wave of patients sharing such sentiments and personal stories of interactions with insurance companies. Conversations at dinner tables, office water coolers, social gatherings and on social media have pivoted to the topic. Many say they hope the new amplified voices can bring about change for companies often accused of valuing profits over people. 2 Pearl Harbor survivors, ages 104 and 102, return to Hawaii to honor those killed in 1941 attack PEARL HARBOR, Hawaii (AP) — The bombing of Pearl Harbor 83 years ago launched the United States into World War II. Two survivors returned to the Hawaii military base on Saturday for a remembrance ceremony on the attack's anniversary. Both are over 100 years old. They joined active-duty troops, veterans and members of the public for an observance hosted by the Navy and the National Park Service. A third survivor was planning to join them but had to cancel due to health issues. The bombing killed more than 2,300 U.S. servicemen. An explosion destroys an apartment block in a Dutch city, killing at least 3 and injuring others THE HAGUE, Netherlands (AP) — An explosion and fire has rocked a neighborhood in the Dutch city of The Hague, killing three people and injuring other people and destroying several apartments. The cause of the disaster is unclear. Emergency authorities said four people were rescued from the rubble and taken to the hospital. The mayor said rescuers were no longer looking for survivors but for eventual bodies, but could not specify how many people might still be unaccounted for. Residents of the northeastern neighborhood of Mariahoeve in The Hague heard a huge bang and screams before dawn. Dutch authorities have deployed a specialized urban search and rescue team to find victims. How 'Mufasa' rose with Aaron Pierre and Blue Ivy's voices along with new Lin-Manuel Miranda music SAN DIEGO (AP) — When Aaron Pierre was cast as Mufasa, the weight of following in the late James Earl Jones’ legendary footsteps was enough to rattle any actor. But instead of letting the pressure roar too loudly, he harnessed his nerves to breathe fresh life into his young lion character. Pierre found parallels between himself and his character while filming his leading role in “Mufasa: The Lion King,” which opens in theaters Dec. 20. He took the reigns as the new voice of Mufasa after Jones played the iconic King Mufasa in both the 1994 and 2019 versions of Disney’s “The Lion King.” The prequel offers a fresh exploration into Mufasa’s origin story.Safety advocates fear Trump will drop long-sought rules to reduce fatal truck crashes

Amazon, Meta each donate $1M to Trump’s inauguration fundRising Drug Production: A Key Driver Transforming The Pharmaceutical Manufacturing Software Market 2024Crypto analyst and pseudonymous trader Dave the Wave has predicted a potential surge in Bitcoin ‘s BTC/USD price before Christmas, citing a favorable technical setup. What Happened : The crypto analyst shared his thoughts on the social media platform X and said that Bitcoin is in an ascending channel. He predicts a possible upward target of around $112,000 by December 25th. Dave the Wave, who accurately predicted the 2021 market collapse, suggests that Bitcoin is also trading within a longer-term ascending channel, similar to the 2021 bull market. A pre-Xmas day #btc rally?😎 pic.twitter.com/pdG0r3GmaL His analysis indicates that Bitcoin could reach between $180,000 and $220,000 in the first half of 2025. #BTC 😬 pic.twitter.com/UKA6wvwsj6 The trader also expressed optimism for altcoins, noting that Bitcoin dominance (BTC.D), a measure of Bitcoin’s share of the digital asset market, appears set to decline, implying a potential rise in altcoins. Also Read: Crypto Expert Who Called 2022 Market Crash Warns About Bitcoin Why It Matters : Dave the Wave’s analysis is based on the idea that Bitcoin operates in four-year cycles. If BTC’s past price action is mirrored, a parabolic move could be imminent. This prediction is significant as it could influence the investment strategies of crypto traders and investors. At the time of the report, BTC was trading at $100,102. Given the volatility of the crypto market, these predictions should be considered with caution. However, they do provide valuable insights into possible market trends and can serve as a guide for investors navigating the crypto space. Read Next Trump Fuels Bitcoin Rally, But Where Will It Go Next Year? Image: Shutterstock © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The African locust bean, a secret superfood, is the unsung hero of many traditional African dishes. This article highlights five creative ways to harness the power of this nutrient-packed ingredient in everyday cooking. Renowned for its flavor-boosting properties and ability to add depth to dishes, the locust bean is revered across different African cultures for its versatility and health benefits. A flavorful twist to soups and stews Adding African locust beans to your soups and stews is a game-changer for flavor. Just a small handful of these fermented beans adds a rich, umami depth to your favorite recipes, making them the perfect secret ingredient for both vegetable and legume-based dishes. Not only do they enhance taste, but they also boost the nutritional value of your meals. Elevating sauces with locust beans Take your everyday sauces to the next level with the magic of locust beans! Whether you're making a classic tomato sauce for pasta or a rich gravy for your rice, adding finely ground locust beans to the mix can elevate your flavors like never before. Not only does it add depth to the taste, but it also creates a velvety texture that makes every bite feel like a treat. Innovative spreads for bread and crackers If you're tired of the same old spreads for your breads and crackers, it's time to get creative with locust beans! By blending mashed locust beans with your favorite herbs and spices, you can whip up delicious spreads that'll make your taste buds sing. Plus, these tasty treats are protein and fiber powerhouses, so they're a smart swap for the usual suspects. A natural thickener in baking Ground African locust beans (powder form) are a fantastic natural thickener for baking recipes. This versatile ingredient can be added to cakes, cookies, and even bread doughs to improve their texture without significantly changing the flavor. Using locust bean powder not only guarantees your baked treats have the perfect consistency but also adds a nutritional punch, making it a wise choice for health-conscious baking. Enhancing breakfast cereals Start your mornings on a healthy note by adding a sprinkle of locust bean powder to your breakfast cereals or porridge. This powder not only adds a delicious flavor but also infuses your morning meal with beneficial vitamins and minerals. It's a super easy way to enhance both taste and nutrition in one go.